Navigation Links
Pluromed Announces Completion of Enrollment in LeGoo™ Cardiac Bypass Clinical Trial
Date:2/5/2010

Pluromed, Inc. has completed enrollment in its LeGoo™ off-pump coronary artery bypass clinical study, based on a protocol reviewed by the U.S. Food and Drug Administration (FDA). When completed, the report of the study will be filed with the FDA as part of the company's submission for U.S. regulatory approval of LeGoo™.

(PRWEB) -- Pluromed, Inc. today announced that it has completed enrollment in its LeGoo™ off-pump coronary artery bypass clinical study, which is evaluating the clinical efficacy of LeGoo™ as compared to a traditional vessel loop. This prospective, randomized trial commenced enrollment in 2008 and has reached its goal of 110 patients, enrolled at 9 hospitals in 4 countries. Principal investigators for the trial were Gerhard Wimmer-Greinecker, M.D., Ph.D., Ardawan Rastan, M.D., Ph.D., Volkmar Falk, M.D., PhD, Olivier Bouchot, M.D., Jan Gummert, M.D., Ph.D., Jean-Philippe Verhoye, M.D., Ph.D., Louis Perrault, M.D., Ph.D., Anno Diegeler, M.D., Ph.D. and Jos G. Maessen, M.D., Ph.D.; Dr. Valavanur A. Subramanian, Chairman of the Department of Cardiothoracic Surgery at The Lenox Hill Heart and Vascular Institute of New-York, served as Chairman of the study’s Data Safety Monitoring Board.

Pluromed’s LeGoo™ is a polymer-based device which is comprised of a non-toxic and biocompatible gel that exists as a liquid at low temperatures and rapidly transitions to a solid at body temperature, forming a plug that can occlude blood vessels. LeGoo™ is injected into a blood vessel that is intended to be occluded, where it stays in a “plug” form for several minutes allowing the surgeon to work in a bloodless field. The gel dissolves with time (spontaneously) or can be reversed back to liquid instantly by cooling the site with ice or irrigating with cold saline. Once dissolved below a minimum concentration, the polymer cannot never re-solidify.

The primary purpose of the study is to demonstrate the clinical safety and efficacy of LeGoo™ in comparison to a standard vessel occlusion method (i.e. vessel loops). Although LeGoo™ is also designed for use in other vascular surgeries where temporary vessel occlusion is desired, this study specifically focuses on the use of LeGoo™ in off-pump coronary bypass (OPCAB, as a most sensitive model of adverse changes that may occur at any vascular site outside of the neurovascular system. The primary endpoint is the proportion of anastomoses (process of suturing the bypass graft to the coronary artery) in which satisfactory hemostasis is achieved.

Dr. William J Cohn, Director of Minimally Invasive Technology at Texas Heart Institute, is the medical director of the study. "With enrollment completed, our focus now turns to data monitoring, completion of follow up and preparation for filing with the U.S. Food and Drug Administration and for primary endpoint publication” said Dr. Cohn. "We are grateful to all the trial investigators who have worked so diligently to reach this milestone."

“This important trial is the latest example of the commitment of leading vascular and cardiovascular surgeons, who seek less traumatic methods to improve patient outcome”, said Jean-Marie Vogel, President and CEO of Pluromed. “We appreciate the participation of the 22 leading physicians and 13 research coordinators, whose efforts led to the successful completion of enrollment."

About Pluromed, Inc.
Pluromed, Inc., Woburn, Massachusetts, founded in 2003, is pioneering the use of atraumatic gel plugs to improve the safety, efficacy and economics of medical interventions. These products potentially address a broad surgery market that includes cardiac and vascular surgery, prostate, kidney and liver surgery, plastic/reconstructive surgery, trauma/battlefield applications and the treatment of kidney stones. They are based on the Company's patented rapid phase transition polymer technology; Pluromed Rapid Transition PolymersÔ (RTP™) are liquid at low temperature and quickly transition to a high viscosity gel at body temperature. Pluromed’s BackStop™, a product used in the treatment of ureteral stones, is cleared for human use in Europe, Canada and the United States. LeGoo™is approved for human use in Europe but is not currently cleared for human use in the USA. For more information, please visit www.pluromed.com

###

Read the full story at http://www.prweb.com/releases/2010/02/prweb3567564.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Pluromed, Inc. Signs Agreement with Boston Scientific
2. Nuvo Research announces early redemption of 5% convertible debentures
3. Good Vibrations Announces Enhanced Education Program
4. Young Innovations, Inc. Announces Record EPS for the Year
5. TeamHealth Holdings, Inc. Announces Fourth Quarter and Full Fiscal 2009 Earnings Release Date and Conference Call
6. Sunquest Announces Significant Speaker Schedule for HIMSS 2010
7. OnlineEducation.com Announces the Addition of Fully Accredited Law and Criminal Justice Degree Programs to its Current Website Offerings
8. OnlineEducation.com Announces Expansion of Liberal Arts & Humanities to its Accredited Online Degree Programs
9. Sinovac Announces Closing of Common Share Offering
10. WellPoint Announces Appearance at Upcoming Conference
11. Healthcare Realty Trust Announces Fourth Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... digital self-scheduling readily available to physicians. The integration will enable Allscripts users ... select appointments via Everseat’s free mobile app. , The partnership gives Everseat substantial ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... 32224, February 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm ... 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: ...
(Date:2/10/2016)... ... 10, 2016 , ... Workrite Ergonomics, who is celebrating their 25th year of ... to being an internationally recognized leader in their industry. , "We are very proud ... President of Workrite. “Workrite recognized the importance of good ergonomics before most of ...
(Date:2/10/2016)... ... ... Anxiety of older Americans over steep cost increases of prescription drugs is at ... to The Senior Citizens League (TSCL). Since last fall, TSCL has ... costs. “The implications are chilling, particularly for people with chronic health problems,” says ...
(Date:2/10/2016)... , ... February 09, 2016 , ... ... and staff helped give free oral screenings to 150 children in kindergarten through ... , The College of Dental Medicine joined Chinese American Dental Society of Southern ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016 Immune Pharmaceuticals ... company, announced today that it has filed a patent ... and other cancers. --> ... cancer by administration of Ceplene (histamine dihydrochloride) in combination ... methods of predicting the efficacy of Ceplene and IL-2 ...
(Date:2/10/2016)... Feb. 10, 2016  The ALS Association, in partnership with ... Challenge to generate a biomarker to track TDP43 aggregation. The ... to a $1 million investment. --> ... that affects nerve cells in the brain and the spinal ... and control muscle movement, which often leads to total paralysis ...
(Date:2/10/2016)... MOUNTAIN VIEW, Calif. , Feb. 10, ... result of a synergistic confluence of various ... unique value propositions, previously unavailable. These opportunities ... convergence and convergence, in turn, drives the ... Today,s entrepreneurial scenario is characterized by technology ...
Breaking Medicine Technology: